Biogen extends collaboration with Eisai
Eisai Co., Ltd. and Biogen Inc. have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. Under the terms of the agreement Eisai has exercised its option to co-develop and copromote aducanumab, Biogen’s investigational anti-amyloid beta (A beta) antibody for patients with Alzheimer’s disease (AD).
The expanded agreement leverages each company’s respective geographic strengths for commercialization and adjusts the respective share of profits from potential sales of aducanumab. Biogen will receive 55 percent of the potential profits in the United States and 68.5 percent of the potential profits in Europe.
Eisai will receive 80 per cent of the potential profits in Japan and Asia (excluding China and South Korea). The companies will have a 50:50 copromotion split of potential profits in the rest of the world. Further, Biogen will book sales in the United States, Europe, and rest of world markets while Eisai will book sales in Japan and Asia (excluding China, South Korea). Biogen will continue to lead the ongoing Phase 3 development of aducanumab and will remain solely responsible for all development costs for aducanumab until April 2018.